Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 54 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Keyword is Antibodies, Monoclonal, Humanized  [Clear All Filters]
2014
Pentheroudakis, G., Kotoula V., Kouvatseas G., Charalambous E., Dionysopoulos D., Zagouri F., et al. (2014).  Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.. Clin Breast Cancer. 14(5), 330-8.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Bisbinas I., Katsarou A., et al. (2014).  Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.. Osteoporos Int. 25(5), 1633-42.
Di Lernia, V., Ricci C., Lallas A., & Ficarelli E. (2014).  Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study.. J Dermatolog Treat. 25(1), 73-4.
Polyzos, S. A., Singhellakis P. N., Naot D., Adamidou F., Malandrinou F. C., Anastasilakis A. D., et al. (2014).  Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene).. J Clin Endocrinol Metab. 99(3), 703-7.
Fountzilas, G., Dafni U., Papadimitriou C., Timotheadou E., Gogas H., Eleftheraki A. G., et al. (2014).  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.. BMC Cancer. 14, 515.
Razis, E., Pentheroudakis G., Rigakos G., Bobos M., Kouvatseas G., Tzaida O., et al. (2014).  EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.. J Cancer Res Clin Oncol. 140(5), 737-48.
Vassilakopoulou, M., Togun T., Dafni U., Cheng H., Bordeaux J., Neumeister V. M., et al. (2014).  In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.. PLoS One. 9(6), e99131.
Kitsou, C., Kosmas I., Lazaros L., Hatzi E., Euaggelou A., Mynbaev O., et al. (2014).  Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.. Gynecol Endocrinol. 30(8), 587-92.
Psyrri, A., Lee J-W., Pectasides E., Vassilakopoulou M., Kosmidis E. K., Burtness B. A., et al. (2014).  Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.. Clin Cancer Res. 20(11), 3023-32.
Gaillard, M-C., Mataftsi A., Balmer A., Houghton S., & Munier F. L. (2014).  ranibizumab in the management of advanced Coats disease Stages 3B and 4: long-term outcomes.. Retina. 34(11), 2275-81.
Konstantinidis, I. T., Do R. K. G., Gultekin D. H., Gönen M., Schwartz L. H., Fong Y., et al. (2014).  Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.. Ann Surg Oncol. 21(8), 2675-83.
Pentheroudakis, G., Kotoula V., Fountzilas E., Kouvatseas G., Basdanis G., Xanthakis I., et al. (2014).  A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).. BMC Cancer. 14, 111.
Symeonidis, C., Dastiridou A., Konidaris V., Brazitikos P., & Androudi S. (2014).  Subretinal fibrosis and uveitis: a spectral domain OCT study of its evolution and the minimal therapeutic effect of the off-label treatment with ranibizumab.. Ocul Immunol Inflamm. 22(6), 497-500.
2013
Pentheroudakis, G., Kotoula V., De Roock W., Kouvatseas G., Papakostas P., Makatsoris T., et al. (2013).  Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.. BMC Cancer. 13, 49.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Bisbinas I., Gerou S., & Makras P. (2013).  Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.. J Clin Endocrinol Metab. 98(8), 3206-12.
Darwiche, K., Zarogoulidis P., Karamanos N. K., Domvri K., Chatzaki E., Constantinidis T. C., et al. (2013).  Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology.. Future Oncol. 9(4), 505-25.
Triantafyllou, A., Pyrpasopoulou A., Anyfanti P., Balaska E., Aslanidis S., & Douma S. (2013).  eLetter: Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors by M Genovese.. Ann Rheum Dis. 72(5), e7.
Martin, V., Landi L., Molinari F., Fountzilas G., Geva R., Riva A., et al. (2013).  HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.. Br J Cancer. 108(3), 668-75.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.